Literature DB >> 1722157

Pathogenesis of benign prostatic hyperplasia.

R J Bosch1.   

Abstract

The pathogenesis of benign prostatic hyperplasia (BPH) remains largely unresolved. Three major theories have evolved over the years, each emphasizing a possible causative mechanism. The first theory, the dihydrotestosterone hypothesis, is based on the failure of BPH to develop in men castrated prior to puberty. The second, the embryonic reawakening theory, assumes a reawakening of the embryonic induction potential of prostatic stroma. The third, or stem cell theory, postulates the development of BPH through an increase in the number of stem cells or through an abnormal increase in clonal expansion of amplifying or transit cells. These mechanisms may act in concert.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722157     DOI: 10.1159/000471742

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  4 in total

Review 1.  Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

2.  Relationship between metabolic syndrome and prostate volume in Korean men under 50 years of age.

Authors:  Sung Jin Yim; Young Sam Cho; Kwan Joong Joo
Journal:  Korean J Urol       Date:  2011-06-17

3.  Relationships between Prostate-Specific Antigen, Prostate Volume, and Components of Metabolic Syndrome in Healthy Korean Men.

Authors:  Hyun Keun Byun; Yun Hsien Sung; Won Kim; Jae Hung Jung; Jae Mann Song; Hyun Chul Chung
Journal:  Korean J Urol       Date:  2012-11-14

4.  Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1α signaling pathway.

Authors:  Jiumao Lin; Jianheng Zhou; Wei Xu; Zhenfeng Hong; Jun Peng
Journal:  Exp Ther Med       Date:  2014-05-19       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.